Prevalence, incidence burden and clinical impact of healthcare-associated infections and antimicrobial resistance: a national prevalent cohort study in acute care hospitals in Greece by Kritsotakis, E. et al.
© 2017 Kritsotakis et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Infection and Drug Resistance 2017:10 317–328
Infection and Drug Resistance Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
317
O R I g I n a l  R e s e a R c h
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IDR.S147459
Prevalence, incidence burden, and clinical 
impact of healthcare-associated infections and 
antimicrobial resistance: a national prevalent 
cohort study in acute care hospitals in greece
evangelos I Kritsotakis1
Flora Kontopidou2
eirini astrinaki3
Maria Roumbelaki4
eleni Ioannidou5
achilles gikas6
1school of health and Related 
Research, Faculty of Medicine, 
Dentistry and health, University of 
sheffield, sheffield, UK; 2healthcare 
associated Infections and 
antimicrobial Resistance Office, 
hellenic center for Disease control 
and Prevention, athens, 3Infection 
control committee, University 
hospital of heraklion, 4Department 
of nursing, Technological educational 
Institute of crete, heraklion, 
5Department of Internal Medicine, 
Rethymnon general hospital, 
Rethymnon, 6Department of Internal 
Medicine and Infectious Diseases, 
University hospital of heraklion, 
heraklion, greece
Background: Assessing the overall burden of healthcare-associated infections (HAIs) is 
challenging, but imperative in evaluating the cost-effectiveness of infection control programs. 
This study aimed to estimate the point prevalence and annual incidence of HAIs in Greece and 
assess the excess length of stay (LOS) and mortality attributable to HAIs, overall and for main 
infection sites and tracer antimicrobial resistance (AMR) phenotypes and pathogens.
Patients and methods: This prevalent cohort study used a nationally representative cross-
section of 8,247 inpatients in 37 acute care hospitals to record active HAIs of all types at baseline 
and overall LOS and in-hospital mortality up to 90 days following hospital admission. HAI 
incidence was estimated using prevalence-to-incidence conversion methods. Excess mortality 
and LOS were assessed by Cox regression and multistate models correcting for confounding 
and time-dependent biases.
Results: HAIs were encountered with daily prevalence of 9.1% (95% confidence interval [CI] 
7.8%–10.6%). The estimated annual HAI incidence was 5.2% (95% CI 4.4%–5.3%), corre-
sponding to approximately 121,000 (95% CI 103,500–123,700) affected patients each year in 
the country. Ninety-day mortality risk was increased by 80% in patients with HAI compared to 
those without HAI (adjusted hazard ratio 1.8; 95% CI 1.3–2.6). Lower respiratory tract infec-
tions, bloodstream infections, and multiple concurrent HAIs doubled the risk of death, whereas 
surgical site and urinary tract infections were not associated with increased mortality. AMR had 
significant impact on the daily risk of 90-day mortality, which was increased by 90%–110% in 
patients infected by carbapenem-resistant gram-negative pathogens. HAIs increased LOS for 
an average of 4.3 (95% CI 2.4–6.2) additional days. Mean excess LOS exceeded 20 days in 
infections caused by major carbapenem-resistant gram-negative pathogens.
Conclusion: HAIs, alongside with increasing AMR, pose significant burden to the hospital 
system. Burden estimates obtained in this study will be valuable in future evaluations of infec-
tion prevention programs.
Keywords: nosocomial infections, antibiotic resistance, length of stay, mortality, prevalence, 
incidence
Introduction
Healthcare-associated infections (HAIs) represent a major issue for healthcare pro-
viders, infection control specialists, public health authorities, and the patients. The 
most recent estimate of the average daily prevalence of HAIs in acute care hospitals 
in Europe is 6%, involving approximately 3.2 million affected patients each year.1 
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The dramatic increase of antimicrobial resistance (AMR) in 
pathogenic bacteria seen in hospital settings worldwide2 has 
resulted in more complications to treat HAIs, and associated 
treatment failure and deaths have risen.3
Even with optimal care, the extent to which HAIs are 
preventable depends on the setting, type of infection, and 
baseline infection rates. Systematic reviews of interventions 
to reduce HAIs have suggested that at least 20% of all HAIs 
are probably avoidable.4 Preventability proportions may 
exceed 50% for surgical site and device-associated infections 
with current evidence-based strategies.5 However, infection 
prevention programs have an associated cost, which should be 
compared with the expected benefits to ensure that the most 
cost-effective measures are implemented.6,7 This requires 
accurate assessment of the overall burden of HAIs in terms 
of excess deaths, length of hospitalization, and costs.6,7
The resources and effort required have rarely allowed 
multicenter studies of the global burden of all types of HAIs 
to be carried out. Consequently, only a handful of epidemio-
logical studies have attempted to assess the impact of all HAIs 
on prolongation of length of stay (LOS) and/or mortality 
in hospital-wide settings.7–11 Moreover, studies attempting 
to provide this information face considerable challenges. 
Patients with HAIs are older, suffer from more chronic dis-
eases, and are generally more ill than patients without HAIs;12 
consequently, patients with HAIs experience long exposure 
to the hospital environment before becoming infected. Such 
confounding effects and time-dependent biases may have 
been inadequately addressed in previous studies.6,13
The aim of this study was to obtain the first national 
estimates of the current prevalence and incidence burden of 
HAIs in acute care hospitals in Greece and assess the excess 
mortality and LOS attributable to HAIs, overall and sepa-
rately for main sites of infection and tracer AMR phenotypes 
and pathogens.
Patients and methods
study design and setting
This prevalent cohort study was based on a baseline survey 
of 8,247 inpatients in 37 hospitals in Greece. The sample 
was a nationally representative cross-section of all patients 
hospitalized in acute care hospitals in a single day and was 
formed as part of the country’s participation in the first pan-
European point prevalence survey of HAIs in June 2012.14 
Mortality and LOS were ascertained at the time of hospital 
discharge and up to 90 days after the baseline survey.
The study was approved by the Review Board of Hel-
lenic Center for Disease Control and Prevention. As data 
collection originated from routine care activities and was 
included in monitoring activities mandated by national 
legislation (Ministerial Decisions Y1/4234/13.6.2001 and 
Y1.114971/18.02.2014), separate approvals by the institu-
tional ethics committees in participating hospitals and patient 
informed consent were not required. Data were anonymous, 
kept confidential, and not linked to individuals. Study results 
are reported according to the STROBE guidelines.
hospital selection criteria and sample 
size
We calculated that a total of 40 hospitals (10,506 patients) 
would be required to estimate an anticipated HAI point 
prevalence of 7%,12 with precision of ±1% at the national 
level, based on an average hospital size of 260 beds and a 
total number of 35,120 beds. We used an estimated design 
effect of 4.5 to account for clustering at the hospital level.14
We recruited hospitals on a voluntary basis using a pur-
posive sampling method. Three criteria were used to frame 
the sample: 1) inclusion of at least one district-referral 
hospital from each of the seven Regional Health Districts 
in the country, 2) inclusion of at least four general hospitals 
from each district, and 3) all included hospitals have a fully 
operational infection control team with prior experience in 
HAI surveillance. We identified 39 hospitals satisfying the 
selection criteria, which we invited to participate; two hos-
pitals refused to participate.
The 37 sampled hospitals comprised 27% of all public 
hospitals in Greece, had 16,164 beds (46% of the coun-
try’s total), and had completed 1,068,311 discharges and 
4,127,210 patient-days in 2011 (46% and 44% of country’s 
total, respectively).
Patient selection criteria
All patients admitted to an acute care ward before 8:00 AM 
and not discharged from the ward at the time of the baseline 
survey were included in the study cohort. Day-case patients 
undergoing same-day treatment or surgery, seen in the 
emergency room or at outpatient departments, and dialysis 
outpatients were excluded.
Data collection and processing
Data were collected by 115 infection control practitioners 
across the country who had attended a 2-day online training 
course based on standardized European Centre for Disease 
Prevention and Control (ECDC) and national training mate-
rials. A help-desk service was provided during data collec-
tion by the Infection Control Unit of University Hospital of 
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Heraklion, which served as the coordinating center for this 
study. All raw data were submitted to the coordinating center 
through a web-based data entry system and underwent central 
data management, including data checking for obvious errors 
and omissions, corrective queries, and statistical analysis.
Data were extracted from review of nursing and medi-
cal records and on the basis of information provided by the 
physicians and nurses in charge of the patients. Data col-
lected for all patients included demographic characteristics, 
comorbid conditions determined by use of the weighted 
Charlson comorbidity index,15 severity of underlying disease 
determined in accordance with the McCabe classification,14 
patient specialty, exposure to invasive devices at baseline, and 
prior surgery in the 30 days preceding the baseline survey. 
Comorbidities were evaluated at the time of hospital admis-
sion. Disease severity was determined in accordance to ECDC 
guidelines,14 and assessed before infection for patients with an 
active HAI and at the day of survey for uninfected patients.
Active HAIs at baseline were identified using the ECDC 
case definitions.14 Data collected for each HAI included 
date of onset, site, microorganisms, and AMR status. For 
purposes of data analysis, HAIs were categorized into lower 
respiratory tract infections (LRTIs) including pneumonias, 
bloodstream infections (BSIs) including catheter-related 
infections, urinary tract infections (UTIs), surgical site 
infections (SSIs), systemic infections including clinical sep-
sis, and other infections. Patients with multiple concurrent 
HAIs were analyzed as a separate group. AMR was assessed 
based on antibiotic susceptibility data that were available at 
the time of the baseline survey. Selected tracer phenotypes 
were recorded, including methicillin-resistant Staphylococcus 
aureus (MRSA); vancomycin-resistant Enterococcus species 
(VRE); third-generation cephalosporins and carbapenems 
for Enterobacteriaceae; and carbapenems for Acinetobacter 
baumannii and Pseudomonas aeruginosa. Intermediate 
sensitive strains were recorded as resistant.
Baseline data collection was completed in a single day at 
the ward/unit level and within a period of 3–4 weeks at the 
hospital level. Patient outcome was recorded as in-hospital 
death, discharge alive, or hospital stay 3 months following the 
baseline survey. Six hospitals did not provide outcome data as 
patient follow-up was an optional part of the study protocol.
statistical analysis
HAI point prevalence was calculated as the number of 
infected patients divided by the total number of patients, 
overall and separately for each site of infection, resistance 
phenotype, and pathogen. Population estimates of prevalence 
proportions were calculated with 95% confidence intervals 
(CI) and were compared across different patient groups using 
chi-square tests accounting for the stratified clustered design 
(by region and hospital) of the baseline survey.
The annual incidence burden of HAIs was quantified by 
estimating the number of patients expected to acquire a HAI 
in a year in acute care hospitals in the country, overall and 
separately by type of HAI and AMR phenotype. This was 
calculated by multiplying the point prevalence estimate by 
the national total of acute care patient-days in the country 
(9,312,024 patient-days in 2011) and dividing the product 
by the average duration of infection. The calculation has 
been described by Freeman and Hutchison,16 and forms the 
basis of the Rhame and Sudderth prevalence-to-incidence 
conversion.17 The estimated number of patients acquiring a 
HAI in a year was divided by the national total of discharges 
(2,344,999 discharges in 2011) to obtain annual cumulative 
incidence proportions for each type of HAI and resistance 
phenotype. Duration of infection was estimated as the interval 
between date of onset of infection and date of baseline survey, 
excluding HAIs present at admission.1,18 Median values were 
used to account for the high degree of right skewness in the 
distribution of infection durations, and associated CIs were 
calculated using bootstrapping.
Multivariable Cox proportional hazards models were 
used to compare the daily risk (hazard) of death between 
patients with HAIs and uninfected patients in terms of 
adjusted hazard ratios (HRs) and associated 95% CIs. The 
day of admission was used as the time variable, and times 
to death within 30 and 90 days of hospital admission were 
the outcome variables in the models. Occurrence of HAI 
was treated as a time-dependent exposure to account for the 
indirect effect on mortality of a potentially extended LOS 
due to HAI. Main infection types and AMR phenotypes were 
examined separately. Baseline covariates were adjusted for in 
the models with the assumption that patient characteristics 
at admission remained unaltered throughout a patient’s stay. 
The models accounted for clustering at the hospital level and 
stratification at the regional level.
Differences in hospital LOS between patients with HAI and 
those without were estimated by a multistate model using the 
“Empirical Transition Matrix” package (version 0.6–2) in R, 
version 3.3.0.19 The model comprised two transient states (hos-
pital admission and HAI) and two absorbing states (discharge 
alive and in-hospital death). HAI was considered an intermedi-
ate state between admission and discharge or death in order to 
mitigate the potential for time-dependent bias, which has been 
shown to overestimate the extra LOS.13,20 This time-adjusted 
 
In
fe
ct
io
n 
an
d 
Dr
ug
 R
es
ist
an
ce
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
3.
16
7.
29
.2
12
 o
n 
18
-O
ct
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Infection and Drug Resistance 2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
320
Kritsotakis et al
estimate of excess LOS cannot be adjusted for other confound-
ers. Associated CIs were calculated using bootstrapping.
Results
studied population
The study cohort consisted of 8,247 inpatients at baseline, 
who had a median age of 63 years (interquartile range [IQR], 
38–76 years) and 54.4% were males. Most patients had an 
emergency admission (74.7%) and were located in tertiary 
care hospitals (63.6%). The median Charlson comorbidity 
index was 1 (IQR, 0–2), and 26.8% of the patients had a 
 rapidly or ultimately fatal underlying disease. At the time 
of the baseline survey, 80.8% were exposed to one or more 
invasive devices and 28.4% had undergone recent surgery. 
Outcome data were obtained for 7,147/8,247 (87%) patients 
in 31/37 (84%) hospitals (Figure 1). Any-cause mortality 
was 3.3% at 30 days and 6.1% at 90 days following hospital 
admission. The median LOS was 11 (IQR, 6–23) days.
characteristics of haIs
A total of 746 patients with an active HAI were identified, of 
whom 71 (9.5%) patients had two concurrent infections and 
Figure 1 Flow chart showing patient inclusion and follow-up in the study and the sample sizes in the analyses of the burden and impact of haI.
Abbreviations: haI, healthcare-associated infection; lOs, length of hospital stay.
Patients recorded in the baseline cross-
sectional sample and included in
the HAI burden analysis:
8,247 patients in 37 hospitals
(746 patients with HAI)
Followed up to record outcome 3 months
after the baseline survey:
7,147 patients in 31 hospitals
(669 patients with HAI)
Study cohorts in the analysis of 
HAI impact on 30-day mortality:
569 patients with
HAI (55 deaths),
6,578 patients without
HAI (182 deaths)
Study cohorts in the analysis of
HAI impact on 90-day mortality:
646 patients with HAI
(150 deaths),
6,501 patients without HAI (284 deaths)
70 patients (21 with HAI)
excluded because of LOS >150 days 
Study cohorts in the analysis of excess length of stay:
648 patients with HAI
(median LOS, 31 days),
6,429 patients without HAI
(median LOS, 10 days)
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three (0.4%) patients had three infections. Among the 820 
recorded episodes of HAI, the most frequent type was LRTI 
(2.7 infections per 100 patients; 26.7% of all infections), 
followed by BSIs (2.1 infections per 100 patients, 20.7% of 
infections), UTIs (1.7 infections per 100 patients; 17.0% of 
infections), SSIs (3.8 infections per 100 operated patients; 
10.9% of infections), and systemic infections (0.7 infections 
per 100 patients; 6.7% of infections). The “other” category 
accounted for an additional 18.0% of HAIs (1.8 infections 
per 100 patients). A total of 222 (27.1%) HAIs were present 
at hospital admission, originating from the same or other 
hospital. The median time from hospital admission to onset 
of infection was 11 (IQR, 6–25) days. The median duration 
of infection was 7.0 (95% CI, 7.0–8.0) days. 
A total of 564 microorganisms were recorded in 449 
(54.8%) of 820 episodes of HAI. The pathogens isolated most 
frequently included Klebsiella species (17.6%), P. aeruginosa 
(16.8%), Acinetobacter species (16.8%), Staphylococcus spe-
cies (9.2%, including 2.7% S. aureus), Enterococcus species 
(8.9%), and Escherichia coli (8.3%). Of the 424 isolates with 
available antibiogram data, 204 (48.1%) had a tracer AMR 
phenotype. Fifty percent (8/16) of S. aureus isolates were 
MRSA; 12.5% (6/48) of enterococci were VRE; and 39.9% 
(48/183) of Enterobacteriaceae, 83% (73/88) of A. bauman-
nii, and 49.4% (44/89) of P. aeruginosa were resistant to 
carbapenems.
haI prevalence and incidence burden
The overall point prevalence of patients with HAI was 9.1% 
(95% CI 7.8–10.6). Table 1 shows HAI prevalence according 
to baseline patient characteristics. HAI prevalence was higher 
in males than in females, varied by patient specialty and 
increased with age, severity of underlying disease, comor-
bidity index, and number of invasive devices. Higher HAI 
prevalence was also observed for patients who had undergone 
recent surgery and those with an emergency admission. 
The highest overall prevalence proportions were observed 
in intensive care patients (32.7%, 95% CI 27.4–38.4), 
patients admitted with a rapidly fatal disease (30.5%, 95% 
CI 25.0–36.7), and those exposed to 3–4 invasive devices 
(47.9%, 95% CI 42.3–53.5).
The total number of patients with at least one HAI on 
any given day in the country was estimated at 2,323 patients 
(95% CI 1,985–2,712). The estimated annual incidence of 
patients acquiring at least one HAI in a year was 5.2% (95% 
CI 4.4%–5.3%), corresponding to an absolute number of 
121,142 patients (95% CI 103,522–123,738) acquiring a HAI 
per year in the country. National estimates of prevalence and 
incidence burden according to type of infection and AMR 
phenotype are shown in Table 2.
Impact of haI on inpatient mortality
Table 3 shows cumulative proportions and HRs for 30-day 
and 90-day mortality according to patient characteristics. No 
major difference in mortality was observed according to sex 
and hospital type. Patients in internal medicine wards and 
intensive care units had significantly higher mortality com-
pared to surgical patients, whereas no deaths were recorded 
in pediatric, gynecology, and obstetrics departments. Patients 
with emergency admission had higher mortality than those 
with elective admission. Mortality increased with age, 
underlying disease severity, comorbidity index, and exposure 
to invasive devices. Mortality was substantially higher for 
patients with HAI at baseline (9.7% and 23.2% at 30 and 90 
days, respectively) than those without HAI (2.8% and 4.4% 
at 30 and 90 days, respectively).
Following adjustment for confounding and time- 
dependent bias in Cox regression, presence of HAI continued 
to show elevated risk of mortality at 30 days (HR=1.3, 95% 
CI 0.7–2.4, p=0.363) and 90 days (HR=1.8, 95% CI 1.3–2.6, 
p=0.001). Table 4 shows case-fatality rates and adjusted 
HRs according to type of infection, resistance phenotype, 
and pathogen. Compared to uninfected patients, increased 
mortality risk was observed for patients with LRTIs, BSIs, 
and multiple concurrent infections. By contrast, no increase 
in the risk of death was observed in patients with UTIs, 
SSIs, systemic infections, or other infections. Mortality risk 
was also increased in patients infected by third-generation 
cephalosporin-resistant Enterobacteriaceae, carbapenem-
resistant Enterobacteriaceae, and carbapenem-resistant 
A. baumannii. No significant impact on mortality was seen 
in patients infected with MRSA or VRE. 
excess length of hospital stay associated 
with haI
Using a multistate model, presence of HAI was found 
to significantly increase LOS for a mean of 4.3 (95% CI 
2.4–6.2) additional days. The time-adjusted mean differ-
ence in LOS between patients with HAI and those without 
HAI varied substantially according to the type of infection 
and ranged from −2.8 (95% CI −6.6–1.0) days in UTIs to 
10.5 (95% CI 5.3–15.8) days in BSIs. High excess LOS 
estimates were obtained in patients with multiple concurrent 
infections (16.6 days; 95% CI 8.9–24.3) and those infected 
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by an antimicrobial-resistant pathogen (16.9 days; 95% CI 
12.9–20.9). Mean excess LOS peaked in patients infected by 
carbapenem-resistant Enterobacteriaceae, P. aeruginosa, or 
A. baumannii (Table 4).
Discussion
In this first attempt to assess the overall burden of HAIs at 
the national level in Greece, we estimated that HAIs are 
encountered with an average daily prevalence of 9.1% (95% 
CI 7.8%–10.6%) in acute care hospitals in the country, and 
at an annual incidence rate of 5.2% (95% CI 4.4%–5.3%) 
involving approximately 121,000 affected patients each 
year in the country. We found that the daily risk of hospital 
death within 90 days of admission was increased by 80% in 
patients with a HAI compared to those without HAI (HR 
1.8, 95% CI 1.3–2.6). Presence of HAI was seen to signifi-
cantly increase hospital LOS for an average of 4.3 (95% CI 
2.4–6.2) additional days. Our site-specific results suggested 
Table 1 comparison of patients with and without haI and population estimates of haI prevalence according to baseline patient 
characteristics
Patient characteristics Group No. (%) of patients HAI prevalence
% (95% CI)a
P-value
With HAI Without HAI
all all 746 (100) 7,501 (100) 9.1 (7.8–10.6) –
sex Male 439 (58.8) 4,048 (54.0) 9.8 (8.3–11.5) 0.005
Female 307 (41.2) 3,453 (46.0) 8.3 (7.0–9.8)
age (years) 0–14 52 (7.0) 941 (12.5) 5.0 (3.0–8.0) <0.001
15–34 47 (6.3) 774 (10.3) 5.7 (4.1–7.8)
35–54 124 (16.6) 1,267 (16.9) 8.9 (7.3–10.8)
55–74 262 (35.1) 2,359 (31.5) 10.0 (8.7–11.5)
75+ 261 (35.0) 2,158 (28.8) 11.1 (9.1–13.3)
hospital type Tertiary-care 532 (71.3) 4,716 (62.9) 10.1 (8.6–11.8) 0.118
Other 214 (28.7) 2,785 (37.1) 7.4 (5.2–10.5)
admission type emergency 616 (82.6) 5,542 (73.9) 10.0 (8.6–11.7) <0.001
elective 130 (17.4) 1,959 (26.1) 6.4 (5.1–8.0)
Patient specialty surgery 193 (25.9) 2,822 (37.6) 6.4 (5.1–8.0) <0.001
Medicine 343 (46.0) 3,067 (40.9) 10.1 (8.7–11.7)
Pediatrics 9 (1.2) 465 (6.2) 2.0 (0.6–6.6)
gynecology, obstetrics 10 (1.3) 441 (5.9) 1.7 (0.9–3.3)
Intensive care 186 (24.9) 415 (5.5) 32.7 (27.4–38.4)
Other 5 (0.7) 291 (3.9) 1.9 (0.9–4.0)
Underlying disease 
severity (Mccabe)
nonfatal 349 (46.8) 5,548 (74.0) 5.8 (4.8–6.9) <0.001
Ultimately fatal 242 (32.4) 1,477 (19.7) 14.4 (12.1–16.9)
Rapidly fatal 140 (18.8) 357 (4.8) 30.5 (25.0–36.7)
Unknown 15 (2.0) 119 (1.6) 10.6 (7.0–15.8)
comorbidity index 
(charlson)
0 187 (25.1) 3,734 (49.8) 4.8 (3.7–6.1) <0.001
1 101 (13.5) 1,030 (13.7) 9.0 (7.5–10.8)
2–3 261 (35.0) 1,615 (21.5) 14.0 (11.7–16.7)
4+ 197 (26.4) 1,122 (15.0) 15.2 (13.4–17.2)
Recent major surgery no 494 (66.2) 5,414 (72.2) 8.4 (7.1–9.9) 0.002
Yes 252 (33.8) 2,087 (27.8) 10.9 (9.1–13.0)
number of invasive, 
devices at baselineb
0 30 (4.0) 1,555 (20.7) 2.0 (1.4–2.9) <0.001
1 242 (32.4) 3,977 (53.0) 5.5 (4.4–6.8)
2 287 (38.5) 1,764 (23.5) 14.1 (11.5–17.1)
3–4 187 (25.1) 205 (2.7) 47.9 (42.3–53.5)
Yes 736 (98.7) 3,778 (50.4) 16.5 (14.1–19.1)
Overall lOs (days)c Median (IQR) 32 (17–56) 10 (5–19) – –
Inpatient mortalityc at 30 daysd 55 (8.2) 182 (2.8) –
at 90 dayse 150 (22.4) 284 (4.4) –
at follow-up end 168 (25.1) 296 (4.6) –
Notes: aPopulation prevalence estimate, accounting for the stratified cluster sampling design of the study. bRecorded invasive devices included urinary, central vascular, and 
peripheral vascular catheters and intubation. cProvided for background information only, as this analysis suffers from length-time bias.13,20 dDeath occurring within 30 days of 
hospital admission. Patients with infection onset after the 30th day were included in the “without haI” group. eDeath occurring within 90 days of hospital admission. Patients 
with infection onset after the 90th day were included in the “without haI” group.
Abbreviations: HAI, healthcare-associated infection; CI, confidence interval; LOS, length of stay; IQR, interquartile range.
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that LRTIs, BSIs, and multiple concurrent HAIs double 
the risk of death in hospitalized patients, whereas SSIs and 
UTIs are not associated with increased mortality. AMR was 
shown to have a significant effect on the risk of in-hospital 
mortality, which was particularly high in patients infected by 
carbapenem-resistant gram-negative pathogens. Infections 
caused by pathogens with tracer AMR phenotypes were 
shown to independently increase hospitalization by more than 
2 weeks (mean excess of 16.9 days, 95% CI 12.9–20.9 days).
Few comparable studies of the global burden of HAIs 
have been performed to date, mostly at the regional or single-
center level,8,9,11,12 and even fewer at the national level.7,10 
Most multicenter studies assessing the impact of HAIs have 
been primarily conducted in intensive care units,21,22 or have 
focused on a single type of HAI and/or resistance pheno-
type.23,24 This is not surprising given the amount of resources 
and effort required to conduct multicenter hospital-wide 
studies of all types of HAI. As in other national-level stud-
ies,7,10 we attempted to make best use of available data from 
a national point prevalence study of HAIs that was combined 
with patient follow-up and linkage to national registry data 
to make projections at the national level. 
Comparison of results between different studies remains 
difficult mainly because of differences in patient case mix 
and methodology.12 Compared to ECDC data from 33 
countries,1 the overall HAI prevalence and incidence rates 
reported in this study rank Greece as 4th and 8th highest 
in Europe, respectively, affirming a significant burden to 
the Greek hospital system. The 30-day case-fatality rate in 
patients with HAI in this study appears to be lower than that 
reported in hospital-wide studies in Finland and Norway 
(8.2% vs 9.8% and 10.8%, respectively),10,11 but the longer 
term case-fatality appears similar to that reported in France 
and previously in Greece and Cyprus (25.1% vs 21.6% and 
27.9%, respectively).8,12 As shown in other studies,7,8,11 we 
also found that patients with BSI or LRTI had increased risk 
of dying during the follow-up period, even after adjusting for 
the effects of age, comorbidity, underlying disease severity, 
and other important risk factors for death. SSIs and UTIs 
were not associated with increased mortality risk, which has 
also been seen by others.7,8,11,25 
The present study is unique, however, in showing the 
significant independent impact of AMR in patient mortality, 
even outside the critical care setting. Indeed, hospital-wide 
Table 2 national estimates of prevalence and incidence burden according to type of haI and antimicrobial resistance status in greek 
acute care hospitals
Duration of  
HAI, days
Point  
prevalence
Patients with a  
HAI, per daya
Annual 
incidence
Patients with a  
HAI, per yearb
Median 95% CI % 95% CI N 95% CI % 95% CI N 95% CI
Type of infection
lower respiratory 7.0 7.0–8.0 2.6 2.0–3.3 660 520–840 1.5 1.2–1.6 34,600 27,200–38,500
Bloodstream 9.0 9.0–10.0 2.0 1.7–2.5 520 420–640 0.9 0.7–1.0 21,200 17,200–23,500
Urinary tract 6.0 5.0–7.0 1.7 1.4–2.1 440 350–540 1.1 1.1–1.2 26,700 25,700–28,400
surgical site 9.0 7.0–12.0 1.0 0.8–1.3 260 200–340 0.4 0.4–0.4 10,500 10,300–10,300
systemic 6.0 5.0–7.0 0.7 0.4–1.1 180 110–290 0.5 0.3–0.6 10,900 8,100–15,100
Other infections 7.0 6.0–7.0 1.8 1.3–2.5 460 330–640 1.0 0.9–1.4 24,200 20,300–33,600
any haI 7.0 7.0–8.0 9.1 7.8–10.6 2,320 1,990–2,710 5.2 4.4–5.3 121,100 103,500–123,700
Resistance phenotypec
sensitive 9.0 7.0–10.0 1.3 1.1–1.7 340 270–420 0.6 0.6–0.7 13,700 14,100–15,400
Resistant 10.0 10.0–11.0 2.7 2.1–3.5 690 530–900 1.1 0.8–1.3 25,100 19,200–29,800
Resistant pathogens
MRsa or VRe 11.0 8.0–16.7 0.1 0.1–0.3 40 20–70 0.1 0.0–0.1 1,300 900–1,500
3gcR enterobacteriaceae 11.0 8.0–14.9 0.5 0.4–0.8 140 100–200 0.2 0.2–0.2 4,600 4,600–4,800
cR enterobacteriaceae 12.0 10.0–12.0 0.9 0.7–1.2 240 180–310 0.3 0.3–0.4 7,300 6,600–9,600
cR P. aeruginosa 9.0 8.0–12.0 0.5 0.3–0.7 120 80–180 0.2 0.2–0.2 4,800 3,600–5,400
cR A. baumannii 9.0 9.0–10.0 1.0 0.7–1.4 250 170–370 0.4 0.3–0.6 10,100 6,900–13,300
Notes: anumbers have been rounded to the nearest tenth. bnumbers have been rounded to the nearest hundredth. cThe “resistant” category includes patients infected 
with MRsa, VRe, 3gcR or cR enterobacteriaceae, cR P. aeruginosa, or cR A. baumannii. all other infections with known antibiotic susceptibility data were categorized as 
“sensitive”. 
Abbreviations: HAI, healthcare-associated infection; CI, confidence interval; N, number of patients; MRSA, methicillin-resistant Staphylococcus aureus; VRe, vancomycin-
resistant Enterococcus species; 3gcR, third-generation cephalosporin resistant; cR, carbapenem resistant; P. aeruginosa, Pseudomonas aeruginosa; A. baumannii, Acinetobacter 
baumannii.
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case-fatality rates at 90 days in this study reached 37% in 
patients infected by third-generation cephalosporin-resistant 
Enterobacteriaceae, 33% in patients infected by carbapenem-
resistant Enterobacteriaceae, and 35% in those infected by 
carbapenem-resistant A. baumannii. Correcting for the effects 
of other important risk factors for death, the daily risk of 
dying within 90 days of admission was shown to increase by 
90%–110% in patients infected by these resistant pathogens 
compared to uninfected patients.
Our overall estimate of the excess LOS due to HAIs 
(4.3 days) is almost identical to the estimate of 4 days from 
the seminal 1981 study of Haley et al,26 which used direct 
attribution by expert reviewers to assess the prolongation of 
LOS due to HAI. By contrast, our excess LOS estimate is 
considerably lower than those given in comparative attribu-
tion studies in Belgium (7.3 days), Greece and Cyprus (10.1 
days), and England (14.1 days).7,12,27 The latter were based on 
time-invariant methods that cannot fully account for the tim-
ing of infection and thereby have most likely overestimated 
the effect of HAI on excess LOS.13,20 In agreement with the 
site-specific estimates of excess LOS obtained in this study, a 
cohort study of hospitalized patients in Australia controlling 
for a comprehensive set of confounders found that UTIs were 
not associated with prolongation of LOS, while LRTIs had 
an excess LOS of 2.6 (95% CI 1.8–3.7) days.6 The latter also 
illustrated that many factors, other than HAI, are  associated 
Table 3 Univariate comparisons of all-cause in-hospital mortality within 30 and 90 days following hospital admission according to 
baseline patient characteristics in 7,147 acute care patients
Patient characteristics Group 30-day mortality 90-day mortality
N (%) HR (95% CI)a N (%) HR (95% CI)a
all all 237 (3.3) – 434 (6.1) –
sex Male 136 (3.5) 1.0 (0.8–1.3) 249 (6.4) 0.9 (0.8–1.1)
Female 101 (3.1) Ref. 185 (5.7) Ref.
age (years) 0–14 1 (0.1) Ref. 4 (0.5) Ref.
15–34 4 (0.6) 5.2 (1.5–17.8) 5 (0.7) 1.8 (0.6–5.6)
35–54 17 (1.4) 10.2 (4.5–23.6) 36 (3.0) 6.1 (2.8–12.9)
55–74 67 (2.9) 20.5 (8.9–47.4) 156 (6.8) 15.2 (7.3–31.9)
75+ 148 (7.2) 48.4 (21.6–108.8) 233 (11.3) 32.4 (15.0–70.4)
hospital type Tertiary care 140 (3.1) 0.6 (0.4–1.0) 276 (6.2) 0.8 (0.5–1.4)
Other 97 (3.6) Ref. 158 (5.9) Ref.
admission type emergency 214 (4.0) 2.6 (1.6–4.2) 370 (6.9) 1.5 (1.0–2.3)
elective 23 (1.3) Ref. 64 (3.6) Ref.
Patient specialty surgery 39 (1.5) Ref. 75 (2.9) Ref.
Medicine 157 (5.2) 3.1 (2.2–4.4) 242 (8.0) 2.3 (1.6–3.3)
Pediatrics 0 (0.0) – 0 (0.0) –
gynecology, obstetrics 0 (0.0) – 0 (0.0) –
Intensive care 41 (8.4) 2.7 (1.8–4.2) 116 (23.6) 2.6 (1.7–4.0)
Other 0 (0.0) – 1 (0.4) –
Underlying disease severity 
(Mccabe)
nonfatal 56 (1.1) Ref. 108 (2.1) Ref.
Ultimately fatal 95 (6.1) 3.7 (2.6–5.2) 169 (10.9) 3.5 (2.5–4.9)
Rapidly fatal 84 (18.3) 8.6 (5.9–12.4) 151 (32.9) 7.1 (5.2–9.9)
Unknown 2 (1.9) 1.1 (0.3–3.6) 6 (5.6) 1.9 (1.1–3.2)
comorbidity index 
(charlson)
0 19 (0.6) Ref. 48 (1.5) Ref.
1 35 (3.5) 4.5 (2.7–7.6) 65 (6.4) 4.3 (3.2–5.9)
2–3 66 (4.0) 4.4 (2.7–7.1) 133 (8.0) 3.8 (2.9–5.0)
4+ 117 (9.9) 8.8 (4.7–16.7) 188 (15.9) 7.4 (4.8–11.6)
Recent major surgery no 202 (3.9) Ref. 343 (6.6) Ref.
Yes 35 (1.8) 0.5 (0.3–0.9) 91 (4.6) 1.0 (0.7–1.3)
number of invasive 
devices at baselineb
0–1 55 (1.1) Ref. 106 (2.1) Ref.
2 139 (8.1) 5.8 (4.2–8.1) 208 (12.2) 4.8 (3.8–6.2)
3–4 43 (12.8) 4.5 (3.1–6.3) 120 (35.7) 4.4 (3.0–6.2)
healthcare-associated 
infection
no 182 (2.8) Ref. 284 (4.4) Ref.
Yes 55 (9.7) 2.3 (1.2–4.1) 150 (23.2) 3.0 (2.3–4.0)
Notes: aHazard ratios were estimated using univariate Cox proportional hazards regression and accounting for the stratified cluster design of the baseline survey. Healthcare-
associated infection was treated as a time-dependent risk factor for death. bRecorded invasive devices included urinary, central vascular, and peripheral vascular catheters 
and intubation.
Abbreviations: N, number of deaths; HR, hazard ratio; CI, confidence interval; Ref., reference category.
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with increased LOS, and omitting these confounders from 
analysis leads to inflated estimates of excess LOS due to 
HAI.6 The multistate modeling used in the current study 
provided estimates of excess LOS that were time adjusted 
but not fully adjusted for other confounders. Time adjustment 
is probably more important than adjustment for confound-
ers as was illustrated by Beyersmann et al who reported that 
accounting for a large number of potential confounders did 
not redeem the overestimation of excess LOS.28 
UTI was the single type of HAI that was associated with 
decreased LOS in this study. This contradicts with the find-
ings of other time-adjusted estimates of excess LOS due to 
UTI obtained from multicenter studies in Spain (4.6 days) 
and Australia (4.0 days). 7,24 Both of the latter seem high 
and might be the result of rather complicated cases of UTIs, 
mainly in elderly patients surviving a prolonged hospitaliza-
tion.7 Indeed, UTIs in intensive care units in 10 developing 
countries were seen to prolong LOS by only 1.6 (95% CI 
0.6–2.6) extra days.29 It is possible, however, that accurately 
estimating excess LOS requires further adjusting for patient 
case mix in addition to accounting for time-dependent bias, 
which is a gap in available statistical methods.
Controlling for time-dependent bias, we found that AMR 
is a major contributing factor in prolonging hospital LOS, 
with the mean excess LOS ranging from 9.6 days in MRSA 
or VRE infections to more than 20 days in infections caused 
by major carbapenem-resistant gram-negative pathogens. 
Using similar statistical methods, a cohort study at a Swiss 
university hospital found that excess LOS attributable to 
MRSA infection was 11.5 (95% CI 7.9–15) days,23 which 
resembles our findings. To the best of our knowledge, no 
other study has assessed the excess LOS due to infections 
caused by carbapenem-resistant gram-negative pathogens in 
hospital-wide settings to date.
Particular limitations in this study should be acknowl-
edged when interpreting our findings. The first relates to the 
absence of global national surveillance data in Greece, which 
compelled us to rely entirely on data from the only existing 
national point prevalence survey to assess the global burden 
of HAIs. It is well known that cohorts of patients gathered 
through sampling prevalent cases tend to have longer sur-
vival times than those obtained in an incident cohort study. 
Our approach to estimating excess mortality assumes that 
the composition of the two patient groups (with HAI and 
without HAI at the time of the baseline survey) and their 
underlying conditions remained constant during follow-up. 
We cannot exclude the possibility that some subjects without 
HAI at baseline may have developed a HAI at a later time; 
depending on the extent of this misclassification, we might 
have underestimated the effect of HAI on mortality. The 
incidence-to-prevalence conversion used in this study also 
requires data from an incidence series of HAIs; we used 
median values to estimate the average duration of HAI cor-
recting for the skewness towards patients with longer duration 
of infection in our sample. Simulations based on Europe-wide 
surveillance data in intensive care units have confirmed that 
incidence-to-prevalence conversion performs well using this 
method,1 although the use of antibiotic treatment as a proxy 
for infection has been reported to improve the method.30 
Nevertheless, we must acknowledge that incident sampling, 
although logistically difficult and more expensive, remains 
the gold standard for estimating HAI incidence and impact 
on LOS and mortality. 
Another limitation relates to the fact that we relied on 
antibiotic susceptibility tests available at the day of the 
baseline survey and thereby were able to assess resistance 
phenotypes for about half of the HAIs recorded in this study. 
This led to reduced sample sizes and thereby wide CIs for 
excess LOS and mortality associated with specific resistance 
phenotypes. Previous experience has shown that extending 
the period of recording microbiology data to a week following 
the detection of an active HAI in a prevalent cohort study 
may increase culture and antibiogram availability to about 
70% of detected infections,12 thereby improving pathogen-
specific burden estimation. Moreover, we did not account 
for treatment factors in our analysis because our objective 
was to assess the real-life effect of AMR. Whether this effect 
was due to intrinsic pathogen factors or treatment failure was 
beyond the scope of this study.
Conclusion
This assessment of the burden of HAIs from a public health-
care provider’s perspective showed that the incidence of HAIs, 
alongside their associated impact on LOS and mortality, 
presents a significant burden to the Greek hospital system. 
These findings, together with the increasing AMR in hospital 
settings, suggest that it is time to consider systematic inter-
ventions to reduce HAI incidence, including the potential of 
developing a global national surveillance system. Burden 
estimates obtained in this study will be valuable in future 
evaluations of the cost-effectiveness of infection prevention 
programs.
Acknowledgments
We thank the infection control teams in all of the participating 
hospitals for their cooperation and support.
 
In
fe
ct
io
n 
an
d 
Dr
ug
 R
es
ist
an
ce
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
3.
16
7.
29
.2
12
 o
n 
18
-O
ct
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Infection and Drug Resistance 2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
327
Burden of healthcare-associated infections
Author contributions
Study conception: EIK, AG; study design: EIK, EA, MR, EI, 
AG; data acquisition: EIK, FK, EA, MR, EI, AG; data manage-
ment and statistical analysis: EIK; drafting of the manuscript: 
EIK; data interpretation and critical revision of the manuscript: 
EIK, FK, EA, MR, EI, AG. All authors approved the final 
manuscript and are accountable for all aspects of this work.
Disclosure
The authors report no conflicts of interest in this work. No 
external funding was received for this work.
References
 1.  European Centre for Disease Prevention and Control. Point Preva-
lence Survey of Healthcare-Associated Infections and Antimicrobial 
Use in European Acute Care Hospitals. Stockholm: ECDC; 2013. 
doi:10.2900/86011.
 2.  Huttner A, Harbarth S, Carlet J, et al. Antimicrobial resistance: a global 
view from the 2013 World Healthcare-Associated Infections Forum. 
Antimicrob Resist Infect Control. 2013;2(1):31.
 3.  Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths 
attributable to carbapenem-resistant Enterobacteriaceae infections. 
Emerg Infect Dis. 2014;20(7):1170–1175.
 4.  Harbarth S, Sax H, Gastmeier P. The preventable proportion of noso-
comial infections: an overview of published reports. J Hosp Infect. 
2003;54(4):258–266.
 5.  Umscheid CA, Mitchell MD, Doshi JA, Agarwal R, Williams K, Brennan 
PJ. Estimating the proportion of healthcare-associated infections that 
are reasonably preventable and the related mortality and costs. Infect 
Control Hosp Epidemiol. 2011;32(2):101–114.
 6.  Graves N, Weinhold D, Tong E, et al. Effect of healthcare-acquired infec-
tion on length of hospital stay and cost. Infect Control Hosp Epidemiol. 
2007;28(3):280–292.
 7.  Vrijens F, Hulstaert F, Devriese S, van de Sande S. Hospital-acquired 
infections in Belgian acute-care hospitals: an estimation of their global 
impact on mortality, length of stay and healthcare costs. Epidemiol 
Infect. 2012;140(1):126–136.
 8.  Fabbro-Peray P, Sotto A, Defez C, et al. Mortality attributable to noso-
comial infection: a cohort of patients with and without nosocomial 
infection in a French university hospital. Infect Control Hosp Epidemiol. 
2007;28(3):265–272.
 9.  García-Martín M, Lardelli-Claret P, Jiménez-Moleón JJ, Bueno-
Cavanillas A, Luna-del-Castillo JD, Gálvez-Vargas R. Proportion of 
hospital deaths potentially attributable to nosocomial infection. Infect 
Control Hosp Epidemiol. 2001;22(11):708–714.
10.  Kanerva M, Ollgren J, Virtanen MJ, Lyytikäinen O; Prevalence Survey 
Study Group. Estimating the annual burden of health care-associated 
infections in Finnish adult acute care hospitals. Am J Infect Control. 
2009;37(3):227–230.
11.  Koch AM, Nilsen RM, Eriksen HM, Cox RJ, Harthug S. Mortality 
related to hospital-associated infections in a tertiary hospital; repeated 
cross-sectional studies between 2004–2011. Antimicrob Resist Infect 
Control. 2015;4(1):57.
12.  Kritsotakis EI, Dimitriadis I, Roumbelaki M, et al. Case-mix adjustment 
approach to benchmarking prevalence rates of nosocomial infection 
in hospitals in Cyprus and Greece. Infect Control Hosp Epidemiol. 
2008;29(8):685–692.
13.  Nelson RE, Nelson SD, Khader K, et al. The Magnitude of Time-
Dependent Bias in the Estimation of Excess Length of Stay Attributable 
to Healthcare-Associated Infections. Infect Control Hosp Epidemiol. 
2015;36(9):1089–1094.
14.  European Centre For Disease Prevention and Control. Point Prevalence 
Survey of Healthcare-Associated Infections and Antimicrobial Use in 
European Acute Care Hospitals. Protocol Version 4.3. Full Scale Survey 
and Codebook. Stockholm: ECDC; 2012. doi:10.2900/53482.
15.  Charlson ME, Pompei P, Ales KL, MacKenzie R. A new method of clas-
sifying prognostic in longitudinal studies: development and validation. 
J Chronic Dis. 1987;40(5):373–383.
16.  Freeman J, Hutchison GB. Prevalence, incidence and duration. Am J 
Epidemiol. 1980;112(5):707–723.
17.  Rhame FS, Sudderth WD. Incidence and prevalence as used in the 
analysis of the occurrence of nosocomial infections. Am J Epidemiol. 
1981;113(1):1–11.
18.  Magill SS, Edwards JR, Bamberg W, et al; Emerging Infections 
Program Healthcare-Associated Infections and Antimicrobial Use 
Prevalence Survey Team. Multistate point-prevalence survey of health 
care-associated infections. N Engl J Med. 2014;370(13):1198–1208.
19.  Allignol A, Schumacher M, Beyersmann J. Empirical transition matrix 
of multi-state models: the etm Package. J Stat Softw. 2011;38(4): 
1–15.
20.  Beyersmann J, Gastmeier P, Wolkewitz M, Schumacher M. An easy 
mathematical proof showed that time-dependent bias inevitably 
leads to biased effect estimation. J Clin Epidemiol. 2008;61(12): 
1216–1221.
21.  Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-
care-associated infections and antimicrobial resistance in patients 
admitted to European intensive-care units: a cohort study. Lancet Infect 
Dis. 2011;11(1):30–38.
22.  Vincent J, Rello J, Marshall J, et al. International study of the 
prevalence and outcomes of infection in intensive care units. JAMA. 
2009;302(21):2323–2329.
23.  Macedo-Viñas M, De Angelis G, Rohner P, et al. Burden of meticillin-
resistant Staphylococcus aureus infections at a Swiss University hospi-
tal: excess length of stay and costs. J Hosp Infect. 2013;84(2):132–137.
24.  Mitchell BG, Ferguson JK, Anderson M, Sear J, Barnett A. Length of 
stay and mortality associated with healthcare-associated urinary tract 
infections: a multi-state model. J Hosp Infect. 2016;93(1):92–99.
25.  Roumbelaki M, Kritsotakis EI, Tsioutis C, Tzilepi P, Gikas A. Surveil-
lance of surgical site infections at a tertiary care hospital in Greece: 
incidence, risk factors, microbiology, and impact. Am J Infect Control. 
2008;36(10):732–738.
26.  Haley RW, Schaberg DR, Crossley KB, Von Allmen SD, McGowan 
JE Jr. Extra charges and prolongation of stay attributable to nosoco-
mial infections: a prospective interhospital comparison. Am J Med. 
1981;70(1):51–58.
27.  Plowman R, Graves N, Griffin MA, et al. The rate and cost of hospital-
acquired infections occurring in patients admitted to selected specialties 
of a district general hospital in England and the national burden imposed. 
J Hosp Infect. 2001;47(3):198–209.
28.  Beyersmann J, Kneib T, Schumacher M, Gastmeier P. Nosocomial 
infection, length of stay, and time-dependent bias. Infect Control Hosp 
Epidemiol. 2009;30(3):273–276.
29.  Rosenthal VD, Dwivedy A, Calderón ME, et al; International Nosoco-
mial Infection Control Consortium (INICC) Members. Time-dependent 
analysis of length of stay and mortality due to urinary tract infections in 
ten developing countries: INICC findings. J Infect. 2011;62(2):136–141.
30.  King C, Aylin P, Holmes A. Converting incidence and prevalence data: 
an update to the rule. Infect Control Hosp Epidemiol. 2014;35(11): 
1432–1433.
 
In
fe
ct
io
n 
an
d 
Dr
ug
 R
es
ist
an
ce
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
3.
16
7.
29
.2
12
 o
n 
18
-O
ct
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Infection and Drug Resistance 2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Infection and Drug Resistance
Publish your work in this journal
Submit your manuscript here: https://www.dovepress.com/infection-and-drug-resistance-journal
Infection and Drug Resistance is an international, peer-reviewed open-
access journal that focuses on the optimal treatment of infection (bacte-
rial, fungal and viral) and the development and institution of preventive 
strategies to minimize the development and spread of resistance. The 
journal is specifically concerned with the epidemiology of antibiotic 
resistance and the mechanisms of resistance development and diffusion 
in both hospitals and the community. The manuscript management 
system is completely online and includes a very quick and fair peer-
review system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
Dovepress
328
Kritsotakis et al
 
In
fe
ct
io
n 
an
d 
Dr
ug
 R
es
ist
an
ce
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
3.
16
7.
29
.2
12
 o
n 
18
-O
ct
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
